Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News and Analysis
  • Published:

InterMune and Boehringer blaze trails for idiopathic pulmonary fibrosis drugs

Nature Reviews Drug Discovery volume 13, pages 483–484 (2014)Cite this article

Subjects

Pirfenidone and nintedanib look set to become the first drugs approved in the United States for idiopathic pulmonary fibrosis, paving a drug development path for more treatments for this deadly disease.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Authors
  1. Katie Kingwell
    View author publications

    You can also search for this author in PubMed Google Scholar

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kingwell, K. InterMune and Boehringer blaze trails for idiopathic pulmonary fibrosis drugs. Nat Rev Drug Discov 13, 483–484 (2014). https://doi.org/10.1038/nrd4382

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd4382

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing